Article
Targeting pancreatic cancer metabolic dependencies through glutamine antagonism - Nature Cancer
Rating:
0.0
Views:
51
Likes:
1
Library:
1
Pancreatic ductal adenocarcinoma (PDAC) cells use glutamine (Gln) to support proliferation and redox balance. Early attempts to inhibit Gln metabolism using glutaminase inhibitors resulted in rapid metabolic reprogramming and therapeutic resistance. Here, we demonstrated that treating PDAC cells with a Gln antagonist, 6-diazo-5-oxo-l-norleucine (DON), led to a metabolic crisis in vitro.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value